Hexarelin: A Potent GHRP with Distinct Cardiac Activity

Research summary. Hexarelin is a synthetic hexapeptide growth hormone secretagogue developed by Romano Deghenghi and colleagues at Mediolanum Farmaceutici in the early 1990s. It is one of the more potent members of the GHRP family at the growth hormone secretagogue receptor (GHS-R1a), and its distinctive feature within the family is its prominent engagement of the scavenger receptor CD36 — which underlies a substantial body of work on hexarelin's cardiac protective activity, somewhat independent of its GH-releasing effects.

Molecular profile

• Sequence: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂
• Molecular formula: C₄₇H₅₈N₁₂O₆
• Molecular weight: ~887.0 g/mol
• PubChem CID: 444656
• CAS Number: 140703-51-1
• Synonyms: examorelin

The key structural distinction from GHRP-6 is the methylated tryptophan at position 2 (D-2-methyl-Trp), which contributes to higher GHS-R1a binding affinity and a longer effective duration of action.

Mechanism of action

Hexarelin engages two receptor systems:

• GHS-R1a (ghrelin receptor): Drives Gαq-mediated GH release from anterior pituitary somatotrophs through phospholipase C activation and calcium mobilisation.
• CD36 scavenger receptor: A separate receptor expressed on cardiomyocytes, endothelial cells, macrophages, and adipose-tissue cells. Hexarelin's CD36 engagement is more pronounced than that of most other GHRPs and is the primary mechanistic basis for its reported cardiac effects.

The dual receptor pharmacology is important to interpretation: hexarelin's cardiac protective effects do not appear to require GH release, having been replicated in hypophysectomised animals and in cardiac preparations ex vivo.

Preclinical research highlights

GH release potency. Among GHRPs, hexarelin has been characterised as among the most potent at GHS-R1a, with reported GH-releasing activity exceeding that of GHRP-6 on a molar basis in comparative studies.

Cardiac protection in ischaemia-reperfusion. A defining body of work in the hexarelin literature involves cardiac ischaemia-reperfusion preparations. Studies in rat and porcine models have reported reduced infarct size, preserved left-ventricular function, attenuated post-ischaemic arrhythmias, and reduced markers of myocyte injury following hexarelin administration. The mechanism is attributed primarily to CD36 engagement on cardiomyocytes.

Cardiac remodelling post-MI. Rat studies of post-myocardial infarction cardiac remodelling have reported attenuation of maladaptive hypertrophy and preserved chamber geometry with hexarelin administration over weeks following the index event.

Hypophysectomised cardiac studies. A particularly informative line of investigation has examined hexarelin in hypophysectomised animals — that is, animals lacking pituitary GH secretory capacity. Cardiac protective effects persisted in these models, demonstrating that hexarelin's cardiac activity is at least partially GH-independent.

Skeletal muscle and bone. Hexarelin administration has been associated with effects on lean mass accretion and bone density in animal models, mediated through GH-IGF-1 axis activation downstream of pituitary GH release.

Diagnostic GH testing. Hexarelin has been used in research and clinical diagnostic contexts as a GH-stimulation test agent, with reliable GH responses in healthy adults.

Position in the GHRP family

Hexarelin sits among related peptides:

• GHRP-2: Slightly less potent at GH release, similar profile to GHRP-6, less prominent CD36 engagement
• GHRP-6: Founding member, prominent CD36 engagement, reliable appetite stimulation
• Ipamorelin: More selective at GHS-R1a, minimal CD36 engagement, minimal cortisol/prolactin effects
• MK-677 (ibutamoren): Non-peptide small molecule, oral bioavailability, no CD36 engagement

For research aimed at studying CD36-mediated cardiac biology, hexarelin is often the preferred tool peptide; for research aimed at isolating GHS-R1a-specific effects, ipamorelin is typically preferred.

A note on doping considerations

Hexarelin is listed by the World Anti-Doping Agency as a prohibited substance under category S2 (peptide hormones, growth factors, related substances and mimetics). Its high GH-releasing potency has made it a long-standing concern in athletic doping, and analytical methods for hexarelin and its metabolites are well-established.

Current research status

Hexarelin remains an investigational research peptide. It is not approved as a therapeutic by any major regulatory authority. Active research applications include:

• Cardiac ischaemia-reperfusion mechanistic studies, particularly via CD36
• GH-axis biology, including comparative GHRP pharmacology
• Skeletal muscle and bone studies in animal models
• Reference compound for development of next-generation GHS-R1a / CD36 agonists

Key takeaways for researchers

• Hexarelin is a hexapeptide GHS-R1a agonist with distinctive engagement of the CD36 scavenger receptor.
• It is among the more potent GHRPs at GH release.
• Its cardiac protective effects in ischaemia-reperfusion models persist in hypophysectomised animals, supporting a GH-independent mechanism mediated through CD36.
• It is on the WADA Prohibited List and is not an approved therapeutic.

References

1. Deghenghi R, Cananzi MM, Torsello A, Battisti C, Muller EE, Locatelli V. GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sciences. 1994;54(18):1321–1328.

---

This article is provided for educational and research purposes only. Hexarelin is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. Hexarelin is listed by the World Anti-Doping Agency as a prohibited substance. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.